Ingalls & Snyder LLC Sells 11,602 Shares of Cardlytics, Inc. (NASDAQ:CDLX)

Ingalls & Snyder LLC decreased its position in shares of Cardlytics, Inc. (NASDAQ:CDLX) by 45.2% in the 4th quarter, Holdings Channel reports. The firm owned 14,050 shares of the company’s stock after selling 11,602 shares during the quarter. Ingalls & Snyder LLC’s holdings in Cardlytics were worth $52,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in CDLX. Tallon Kerry Patrick bought a new stake in shares of Cardlytics in the 4th quarter valued at $37,000. Atom Investors LP bought a new stake in shares of Cardlytics in the 3rd quarter valued at $33,000. SG Americas Securities LLC acquired a new stake in Cardlytics in the 3rd quarter valued at $45,000. Intech Investment Management LLC acquired a new stake in Cardlytics in the 3rd quarter valued at $47,000. Finally, Quadrature Capital Ltd acquired a new stake in Cardlytics in the 3rd quarter valued at $63,000. Institutional investors own 68.10% of the company’s stock.

Insiders Place Their Bets

In other Cardlytics news, CFO Alexis Desieno sold 8,854 shares of Cardlytics stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $3.67, for a total transaction of $32,494.18. Following the transaction, the chief financial officer now directly owns 121,976 shares of the company’s stock, valued at $447,651.92. The trade was a 6.77 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Amit Gupta sold 15,160 shares of Cardlytics stock in a transaction on Friday, January 24th. The stock was sold at an average price of $3.92, for a total value of $59,427.20. Following the sale, the chief executive officer now owns 215,494 shares in the company, valued at $844,736.48. The trade was a 6.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 39,819 shares of company stock valued at $148,305 in the last three months. 4.40% of the stock is currently owned by insiders.

Cardlytics Price Performance

CDLX opened at $3.56 on Friday. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.18 and a quick ratio of 1.18. The company has a market capitalization of $180.93 million, a price-to-earnings ratio of -0.58 and a beta of 1.54. The firm’s fifty day moving average price is $3.49 and its two-hundred day moving average price is $3.85. Cardlytics, Inc. has a 1 year low of $2.76 and a 1 year high of $20.52.

Analyst Upgrades and Downgrades

CDLX has been the subject of several research reports. Craig Hallum raised shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 6th. Needham & Company LLC reissued a “hold” rating on shares of Cardlytics in a research report on Friday, January 17th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $6.92.

Cardlytics Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.